Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enobosarm - Veru Healthcare

Drug Profile

Enobosarm - Veru Healthcare

Alternative Names: GTx-024; MK-2866; Ostarine; S-22; VERU-024

Latest Information Update: 19 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio State University Research Foundation; University of Tennessee Research Foundation
  • Developer Oncternal Therapeutics, Inc.; Veru Healthcare
  • Class Antineoplastics; Nitriles; Small molecules
  • Mechanism of Action Selective androgen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • Discontinued Cachexia; Duchenne muscular dystrophy; Muscular atrophy; Stress incontinence

Most Recent Events

  • 12 May 2022 Veru Healthcare initiates enrolment in the phase III ENABLAR-2 trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA in May 2022
  • 10 May 2022 Phase-III clinical trials in Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Spain (PO) (NCT04869943)
  • 25 Apr 2022 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top